NYSE:RMD - ResMed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$103.12 -0.01 (-0.01 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$103.12
Today's Range$102.89 - $103.36
52-Week Range$69.59 - $104.78
Volume487,483 shs
Average Volume687,847 shs
Market Capitalization$14.72 billion
P/E Ratio36.57
Dividend Yield1.36%

About ResMed (NYSE:RMD)

ResMed logoResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment


Debt-to-Equity Ratio0.39
Current Ratio3.48
Quick Ratio2.85


Trailing P/E Ratio36.57
Forward P/E Ratio29.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.07 billion
Price / Sales7.12
Cash Flow$3.6195 per share
Price / Cash28.49
Book Value$14.48 per share
Price / Book7.12


EPS (Most Recent Fiscal Year)$2.82
Net Income$342.28 million
Net Margins13.52%
Return on Equity23.72%
Return on Assets13.66%


Outstanding Shares142,740,000

ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, April 26th. Investors of record on Thursday, May 10th will be given a dividend of $0.35 per share on Thursday, June 14th. This represents a $1.40 annualized dividend and a yield of 1.36%. The ex-dividend date is Wednesday, May 9th. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed (NYSE:RMD) issued its quarterly earnings results on Thursday, April, 26th. The medical equipment provider reported $0.92 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.85 by $0.07. The medical equipment provider had revenue of $591.60 million for the quarter, compared to the consensus estimate of $575.75 million. ResMed had a return on equity of 23.72% and a net margin of 13.52%. The business's revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.71 earnings per share. View ResMed's Earnings History.

When is ResMed's next earnings date?

ResMed is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for ResMed.

What price target have analysts set for RMD?

12 equities research analysts have issued 12 month price objectives for ResMed's stock. Their forecasts range from $55.00 to $90.00. On average, they anticipate ResMed's share price to reach $68.80 in the next year. View Analyst Ratings for ResMed.

What are Wall Street analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:
  • 1. According to Zacks Investment Research, "ResMed exited the third quarter on a promising note. The company achieved solid double-digit global revenue growth in the quarter, led by sales from Software-as-a-Service businesses as well as new mask products and devices. The company is also focusing on product innovation through research and development. In terms of recent developments, the company recently received reimbursement approval for mandibular repositioning devices in France. Further, the company announced that South Korea will start reimbursing diagnosis and therapeutic treatment for sleep apnea in the near term. All these factors boost investor faith in the stock. Over the past three months, ResMed has outperformed its industry. Yet, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to challenging pricing scenario. Rising costs and a weak gross margin are other concerns." (5/25/2018)
  • 2. Needham & Company LLC analysts commented, "We worked with Sleep Review magazine to survey US sleep centers. The survey included 136 responses received between 1/30/18 and 2/19/18. Compared to our prior (3Q17) survey, actual last-12-month patient volume growth decreased slightly while expected next-12-month patient volume growth increased slightly. RMD’s flow generator ratings were in line with Respironics’ ratings while RMD’s mask ratings were the highest but only slightly above its competitors’ ratings. RMD looks likely to gain branded flow generator prescription share but to lose branded mask prescription share. Overall, we think that the survey is mixed for RMD and we maintain our Hold rating." (3/7/2018)

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:
  • Mr. Michael J. Farrell BE, SM, MBA, Chief Exec. Officer and Director (Age 46)
  • Mr. Robert A. Douglas, Pres & COO (Age 58)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 51)
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 59)
  • Mr. James Hollingshead, Pres of Sleep Bus. (Age 55)

Has ResMed been receiving favorable news coverage?

Press coverage about RMD stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ResMed earned a media sentiment score of 0.12 on Accern's scale. They also gave news articles about the medical equipment provider an impact score of 46.80 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are ResMed's major shareholders?

ResMed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.84%), Baillie Gifford & Co. (3.41%), Northern Trust Corp (1.15%), JPMorgan Chase & Co. (0.68%), Millennium Management LLC (0.54%) and Legal & General Group Plc (0.52%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Bahl & Gaynor Inc., Guggenheim Capital LLC, Swiss National Bank, Baillie Gifford & Co., Northern Trust Corp, Copeland Capital Management LLC, Prudential Financial Inc. and Russell Investments Group Ltd.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Which major investors are buying ResMed stock?

RMD stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Rockefeller Capital Management L.P., Great Lakes Advisors LLC, Bellevue Group AG, State of Tennessee Treasury Department, BlackRock Inc. and Eaton Vance Management. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $103.12.

How big of a company is ResMed?

ResMed has a market capitalization of $14.72 billion and generates $2.07 billion in revenue each year. The medical equipment provider earns $342.28 million in net income (profit) each year or $2.82 on an earnings per share basis. ResMed employs 6,080 workers across the globe.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

MarketBeat Community Rating for ResMed (RMD)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  465 (Vote Underperform)
Total Votes:  682
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ResMed (NYSE:RMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for ResMed in the last 12 months. Their average twelve-month price target is $68.80, suggesting that the stock has a possible downside of 33.28%. The high price target for RMD is $90.00 and the low price target for RMD is $55.00. There are currently 3 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.921.922.001.91
Ratings Breakdown: 3 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $68.80$68.80$68.80$64.50
Price Target Upside: 33.28% downside29.75% downside21.38% downside23.60% downside

ResMed (NYSE:RMD) Consensus Price Target History

Price Target History for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018UBSDowngradeBuy ➝ NeutralMediumView Rating Details
4/16/2018William BlairReiterated RatingOutperformLowView Rating Details
4/4/2018CitigroupDowngradeBuy ➝ NeutralMediumView Rating Details
3/7/2018Needham & Company LLCReiterated RatingHoldMediumView Rating Details
1/23/2018Northland SecuritiesUpgradeUnder Perform ➝ Market PerformHighView Rating Details
1/23/2018MacquarieDowngradeNeutral ➝ SellHighView Rating Details
1/23/2018BMO Capital MarketsBoost Price TargetMarket Perform$90.00HighView Rating Details
10/30/2017JPMorgan Chase & Co.Boost Price TargetOverweight$72.00 ➝ $73.00N/AView Rating Details
10/27/2017BarclaysBoost Price TargetUnderweight$68.00 ➝ $70.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingSell$56.00N/AView Rating Details
8/8/2017Credit Suisse GroupDowngradeOutperform ➝ NeutralLowView Rating Details
8/2/2017Bank of AmericaDowngradeBuy ➝ NeutralHighView Rating Details
2/6/2017Canaccord GenuityReiterated RatingHold$59.00N/AView Rating Details
(Data available from 5/26/2016 forward)


ResMed (NYSE:RMD) Earnings History and Estimates Chart

Earnings by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Earnings Estimates

2018 EPS Consensus Estimate: $3.07
2019 EPS Consensus Estimate: $3.42
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.63$0.65$0.64
Q2 20182$0.74$0.77$0.76
Q3 20182$0.79$0.79$0.79
Q4 20182$0.85$0.92$0.89
Q1 20192$0.72$0.76$0.74
Q2 20192$0.89$0.91$0.90
Q3 20192$0.82$0.91$0.87
Q4 20192$0.86$0.96$0.91

ResMed (NYSE RMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018$0.94N/AView Earnings Details
4/26/2018Q3 2018$0.85$0.92$575.75 million$591.60 millionViewN/AView Earnings Details
1/22/2018Q2 2018$0.78$1.00$583.77 million$601.27 millionViewListenView Earnings Details
10/26/2017Q1 2018$0.66$0.66$506.08 million$523.66 millionViewN/AView Earnings Details
8/1/2017Q4 2017$0.75$0.77$557.68 million$556.69 millionViewListenView Earnings Details
4/27/2017Q3 2017$0.70$0.71$525.84 million$514.20 millionViewN/AView Earnings Details
1/23/2017Q217$0.70$0.73$518.60 million$530.40 millionViewN/AView Earnings Details
10/25/2016Q117$0.64$0.62$475.05 million$465.45 millionViewListenView Earnings Details
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
10/28/2010Q1 2011$0.32$0.36ViewN/AView Earnings Details
8/5/2010Q4 2010$0.33$0.34ViewN/AView Earnings Details
4/29/2010Q3 2010$0.29$0.32ViewN/AView Earnings Details
2/4/2010Q2 2010$0.28$0.31ViewN/AView Earnings Details
11/5/2009Q1 2010$0.25$0.29ViewN/AView Earnings Details
8/6/2009Q4 2009$0.27$0.31ViewN/AView Earnings Details
5/7/2009Q3 2009$0.23$0.25ViewN/AView Earnings Details
2/5/2009Q2 2009$0.21$0.22ViewN/AView Earnings Details
11/6/2008Q1 2009$0.19$0.18ViewN/AView Earnings Details
8/5/2008Q4 2008$0.19$0.19ViewN/AView Earnings Details
5/1/2008Q3 2008$0.20$0.19ViewN/AView Earnings Details
2/7/2008Q2 2008$0.20$0.18ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


ResMed (NYSE:RMD) Dividend Information

ResMed pays an annual dividend of $1.40 per share, with a dividend yield of 1.36%. RMD's next quarterly dividend payment will be made on Thursday, June 14. The company has grown its dividend for the last 2 consecutive years and is increasing its dividend by an average of 8.70% each year. ResMed pays out 49.65% of its earnings out as a dividend.
Next Dividend:6/14/2018
Annual Dividend:$1.40
Dividend Yield:1.36%
Dividend Growth:8.70% (3 Year Average)
Payout Ratio(s):49.65% (Trailing 12 Months of Earnings)
39.66% (Based on This Year's Estimates)
38.36% (Based on Next Year's Estimates)
38.68% (Based on Cash Flow)
Track Record:2 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ResMed (NYSE RMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.77%
Institutional Ownership Percentage: 62.27%
Insider Trading History for ResMed (NYSE:RMD)
Insider Trading History for ResMed (NYSE:RMD)

ResMed (NYSE RMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Brett SandercockCFOSell2,000$101.52$203,040.0069,072View SEC Filing  
5/8/2018Gary W PaceDirectorSell28,403$97.37$2,765,600.11128,981View SEC Filing  
5/3/2018David PendarvisInsiderSell2,810$95.91$269,507.1098,043View SEC Filing  
5/1/2018James HollingsheadInsiderSell600$94.69$56,814.0061,261View SEC Filing  
4/16/2018Brett SandercockCFOSell2,000$99.36$198,720.0071,072View SEC Filing  
4/2/2018James HollingsheadInsiderSell600$98.19$58,914.0059,940View SEC Filing  
3/15/2018Brett SandercockCFOSell2,000$98.53$197,060.0073,072View SEC Filing  
3/5/2018David PendarvisInsiderSell2,810$94.08$264,364.8097,263View SEC Filing  
3/1/2018James HollingsheadInsiderSell600$94.01$56,406.00View SEC Filing  
2/15/2018Brett SandercockCFOSell2,000$93.42$186,840.0075,072View SEC Filing  
2/5/2018David PendarvisInsiderSell2,810$96.03$269,844.3097,263View SEC Filing  
2/1/2018Brett SandercockCFOSell1,250$100.13$125,162.5077,072View SEC Filing  
2/1/2018Richard MchaleInsiderSell2,000$100.12$200,240.0062,002View SEC Filing  
1/26/2018John P WarehamDirectorSell25,934$102.25$2,651,751.5038,934View SEC Filing  
1/24/2018Ronald R TaylorDirectorSell4,885$99.71$487,083.3521,751View SEC Filing  
1/2/2018Brett SandercockCFOSell1,250$84.99$106,237.5078,322View SEC Filing  
1/2/2018James HollingsheadInsiderSell600$84.96$50,976.0062,602View SEC Filing  
12/4/2017David PendarvisInsiderSell2,804$84.17$236,012.6897,257View SEC Filing  
12/1/2017Brett SandercockCFOSell1,250$85.36$106,700.0079,572View SEC Filing  
11/20/2017James HollingsheadInsiderSell7,019$84.16$590,719.0466,409View SEC Filing  
11/9/2017Peter C FarrellDirectorSell118,392$82.70$9,791,018.40306,615View SEC Filing  
11/6/2017Peter C FarrellDirectorSell20,000$83.53$1,670,600.00314,800View SEC Filing  
11/3/2017David PendarvisInsiderSell6,364$82.20$523,120.80View SEC Filing  
11/1/2017Brett SandercockCFOSell1,250$84.50$105,625.0071,772View SEC Filing  
10/4/2017Peter C FarrellDirectorSell20,000$77.01$1,540,200.00View SEC Filing  
10/3/2017David PendarvisInsiderSell6,364$76.94$489,646.16View SEC Filing  
10/2/2017Brett SandercockCFOSell1,250$77.05$96,312.5064,691View SEC Filing  
9/5/2017David PendarvisInsiderSell6,364$77.21$491,364.4493,172View SEC Filing  
9/5/2017Peter C FarrellDirectorSell20,000$76.74$1,534,800.00314,800View SEC Filing  
9/1/2017Brett SandercockCFOSell1,250$77.56$96,950.0065,941View SEC Filing  
8/9/2017Richard SulpizioDirectorSell24,390$73.85$1,801,201.5028,819View SEC Filing  
8/4/2017Peter C FarrellDirectorSell20,000$75.15$1,503,000.00321,557View SEC Filing  
8/3/2017David PendarvisInsiderSell6,364$72.10$458,844.4084,476View SEC Filing  
8/1/2017Brett SandercockCFOSell1,250$77.49$96,862.5059,258View SEC Filing  
7/14/2017James HollingsheadInsiderSell7,140$77.43$552,850.20View SEC Filing  
7/5/2017Peter C FarrellDirectorSell20,000$76.50$1,530,000.00321,557View SEC Filing  
7/3/2017Brett SandercockCFOSell1,250$77.44$96,800.0060,508View SEC Filing  
7/3/2017David PendarvisInsiderSell6,364$77.36$492,319.0484,476View SEC Filing  
6/29/2017Jr. Gregor K EmmertInsiderBuy282,000$0.07$19,740.00
6/28/2017Jr. Gregor K EmmertInsiderBuy424,000$0.06$25,440.00
6/22/2017Richard SulpizioDirectorSell65,887$77.82$5,127,326.344,429View SEC Filing  
6/15/2017Gary W PaceDirectorSell24,390$76.00$1,853,640.0099,317View SEC Filing  
6/5/2017David PendarvisInsiderSell6,365$72.62$462,226.3084,477View SEC Filing  
6/5/2017Peter C FarrellDirectorSell20,000$72.65$1,453,000.00321,557View SEC Filing  
6/1/2017Brett SandercockCFOSell1,250$71.02$88,775.00View SEC Filing  
5/4/2017Peter C FarrellDirectorSell20,000$68.75$1,375,000.00321,557View SEC Filing  
5/3/2017David PendarvisInsiderSell6,365$69.55$442,685.7584,261View SEC Filing  
5/1/2017Brett SandercockCFOSell1,250$68.60$85,750.0062,783View SEC Filing  
4/17/2017James HollingsheadInsiderSell7,139$68.37$488,093.4344,934View SEC Filing  
4/4/2017Peter C FarrellDirectorSell20,000$70.67$1,413,400.00321,557View SEC Filing  
4/3/2017Brett SandercockCFOSell1,250$71.65$89,562.5064,033View SEC Filing  
4/3/2017David PendarvisInsiderSell6,365$71.59$455,670.3584,261View SEC Filing  
3/1/2017Brett SandercockCFOSell1,250$72.48$90,600.0065,283View SEC Filing  
2/24/2017John P WarehamDirectorSell28,403$71.77$2,038,483.3141,403View SEC Filing  
2/20/2017Christopher G RobertsDirectorSell10,000$71.91$719,100.00145,610View SEC Filing  
2/15/2017Franz KozichDirectorBuy50,000$0.05$2,500.00
2/14/2017Warren Russell HawkinsDirectorBuy60,000$0.05$3,000.00
2/6/2017Peter C FarrellDirectorSell20,000$68.32$1,366,400.00321,557View SEC Filing  
2/3/2017David PendarvisInsiderSell6,365$67.16$427,473.4084,261View SEC Filing  
1/17/2017James HollingsheadInsiderSell7,084$64.44$456,492.9646,754View SEC Filing  
1/4/2017Peter C FarrellDirectorSell20,000$62.14$1,242,800.00321,557View SEC Filing  
1/3/2017David PendarvisInsiderSell6,365$61.95$394,311.7584,261View SEC Filing  
12/5/2016David PendarvisInsiderSell6,365$60.00$381,900.0084,261View SEC Filing  
12/5/2016Peter C FarrellDirectorSell20,000$59.83$1,196,600.00372,407View SEC Filing  
11/4/2016Peter C FarrellDirectorSell20,000$57.28$1,145,600.00367,978View SEC Filing  
11/3/2016David PendarvisInsiderSell6,033$57.79$348,647.07View SEC Filing  
10/18/2016James HollingsheadInsiderSell1,967$64.71$127,284.5745,513View SEC Filing  
10/17/2016James HollingsheadInsiderSell5,264$64.43$339,159.5252,744View SEC Filing  
10/17/2016Michael J FarrellCEOSell5,975$64.25$383,893.75203,781View SEC Filing  
10/4/2016Peter C FarrellDirectorSell20,000$64.70$1,294,000.00364,063View SEC Filing  
10/3/2016David PendarvisInsiderSell6,000$63.95$383,700.0087,061View SEC Filing  
9/15/2016Michael J. FarrellCEOSell5,975$64.84$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000$67.18$403,080.0087,061View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000$67.29$1,345,800.00367,978View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000$69.93$2,517,480.00129,158View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487$69.13$171,926.3116,729View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102$69.25$1,599,813.5016,729View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975$70.41$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000$70.50$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000$70.15$2,525,400.00101,887View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390$70.32$1,715,104.8037,390View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000$69.16$1,383,200.00367,978View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000$68.86$413,160.0080,512View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975$65.03$388,554.25154,814View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753$65.02$179,000.0640,669View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000$63.62$1,272,400.00367,978View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000$63.62$381,720.0080,512View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458$59.40$264,805.2043,422View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975$59.63$356,289.25154,814View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000$59.82$1,196,400.00367,978View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000$59.41$356,460.0080,512View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975$57.64$344,399.00154,723View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000$55.90$1,118,000.00367,978View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000$56.02$336,120.0080,287View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975$59.34$354,556.50154,723View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000$58.70$352,200.0080,287View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00367,978View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500$58.57$263,565.0047,569View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975$58.57$349,955.75150,852View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000$60.00$2,160,000.00129,158View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00367,978View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000$57.26$343,560.0080,287View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946$57.06$111,038.7676,300View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000$57.61$1,728,300.00132,136View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000$57.88$2,083,680.00101,887View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980$57.31$8,022,253.80347,978View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975$58.20$347,745.00144,878View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000$57.70$1,154,000.00347,978View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000$57.43$344,580.0074,287View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000$0.0350$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975$53.07$317,093.25144,878View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000$52.16$312,960.0074,287View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000$52.22$1,044,400.00347,978View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337$52.97$335,670.8931,304View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500$55.95$251,775.0052,069View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000$59.38$356,280.0074,287View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333$59.77$378,523.4131,304View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000$0.0550$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000$0.0550$165.00
11/20/2015Christopher G RobertsDirectorSell12,000$59.03$708,360.00109,610View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975$57.03$340,754.25144,878View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442$57.72$1,468,512.2413,684View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333$57.60$364,780.8068,391View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000$57.01$171,030.0083,214View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975$55.35$330,716.25172,370View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500$52.47$288,585.0077,180View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333$52.13$330,139.2968,179View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169$50.93$1,383,717.17289,826View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455$50.67$225,734.8567,680View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975$50.89$304,067.75172,370View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500$51.78$284,790.0077,180View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333$52.04$329,569.3275,316View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000$50.82$1,829,520.00289,826View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000$52.26$313,560.0083,214View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860$51.83$562,873.8061,527View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975$55.54$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975$57.59$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500$55.19$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000$55.61$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333$56.59$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975$57.87$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500$59.41$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000$59.25$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333$59.22$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500$65.10$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500$72.60$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000$70.70$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333$70.67$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000$0.09$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000$0.08$800.00
3/16/2015Anne ReiserInsiderSell4,000$69.10$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975$69.10$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000$66.75$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000$64.64$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333$64.39$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000$66.11$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500$62.35$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000$63.49$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670$62.82$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333$62.35$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000$61.97$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000$66.77$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500$57.09$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000$56.99$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000$56.99$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000$53.28$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000$52.93$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000$52.39$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557$52.00$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000$51.84$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204$51.84$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000$49.84$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000$49.11$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200$52.41$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000$52.99$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000$53.23$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000$53.23$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000$53.37$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000$49.12$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000$49.04$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000$48.95$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200$49.22$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000$50.04$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000$50.09$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200$53.20$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000$49.76$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000$49.57$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000$49.73$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700$50.54$186,998.00106,655View SEC Filing  
5/13/2014John WarehamDirectorSell18,000$51.00$918,000.0013,000View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000$50.00$250,000.0066,423View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290$50.00$214,500.0071,423View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000$49.80$1,245,000.00304,990View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000$49.75$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000$50.01$750,150.0068,956View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000$48.01$3,600,750.00304,990View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000$44.95$224,750.0068,956View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.0084,215View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00489,876View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00100,572View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.0094,902View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.0026,285View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.5218,588View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00123,892View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00880,000View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00109,012View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.0090,000View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


ResMed (NYSE RMD) News Headlines

Analyzing ResMed (RMD) and Apollo Endosurgery (APEN)Analyzing ResMed (RMD) and Apollo Endosurgery (APEN)
www.americanbankingnews.com - May 25 at 9:49 AM
ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective ...ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective ...
www.businesswire.com - May 20 at 5:27 PM
ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective Treatment for COPDResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective Treatment for COPD
finance.yahoo.com - May 20 at 5:27 PM
ResMed (RMD) Receives Consensus Rating of "Hold" from AnalystsResMed (RMD) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 20 at 3:33 PM
Form 4 RESMED INC For: May 15 Filed by: Sandercock BrettForm 4 RESMED INC For: May 15 Filed by: Sandercock Brett
www.streetinsider.com - May 17 at 9:00 AM
Insider Selling: ResMed (RMD) CFO Sells 2,000 Shares of StockInsider Selling: ResMed (RMD) CFO Sells 2,000 Shares of Stock
www.americanbankingnews.com - May 16 at 10:29 PM
Zacks: Brokerages Expect ResMed (RMD) Will Announce Quarterly Sales of $616.39 MillionZacks: Brokerages Expect ResMed (RMD) Will Announce Quarterly Sales of $616.39 Million
www.americanbankingnews.com - May 12 at 2:24 AM
$0.92 EPS Expected for ResMed (RMD) This Quarter$0.92 EPS Expected for ResMed (RMD) This Quarter
www.americanbankingnews.com - May 10 at 5:19 PM
ResMeds New QuietAir Diffuser Vent for CPAP Masks Reduces Noise by 89 PercentResMed's New QuietAir Diffuser Vent for CPAP Masks Reduces Noise by 89 Percent
www.businesswire.com - May 10 at 5:17 PM
Form 4 RESMED INC For: May 08 Filed by: PACE GARY WForm 4 RESMED INC For: May 08 Filed by: PACE GARY W
www.streetinsider.com - May 10 at 5:17 PM
Gary W. Pace Sells 28,403 Shares of ResMed (RMD) StockGary W. Pace Sells 28,403 Shares of ResMed (RMD) Stock
www.americanbankingnews.com - May 10 at 7:31 AM
ResMed Inc. (RMD) Ex-Dividend Date Scheduled for May 09, 2018ResMed Inc. (RMD) Ex-Dividend Date Scheduled for May 09, 2018
www.nasdaq.com - May 8 at 5:05 PM
ResMed (RMD) Insider Sells $269,507.10 in StockResMed (RMD) Insider Sells $269,507.10 in Stock
www.americanbankingnews.com - May 4 at 10:14 PM
ResMed Inc. (RMD) Insider James Hollingshead Sells 600 SharesResMed Inc. (RMD) Insider James Hollingshead Sells 600 Shares
www.americanbankingnews.com - May 2 at 1:24 PM
ResMed (RMD) Downgraded by Zacks Investment ResearchResMed (RMD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 1 at 10:02 AM
ResMed Inc. to Post FY2018 Earnings of $3.50 Per Share, William Blair Forecasts (RMD)ResMed Inc. to Post FY2018 Earnings of $3.50 Per Share, William Blair Forecasts (RMD)
www.americanbankingnews.com - April 30 at 3:40 AM
Global Sleep Apnea Devices Market Forecasts to 2023 - A $6.5 Billion Market Opportunity with ResMed, Koninklijke ...Global Sleep Apnea Devices Market Forecasts to 2023 - A $6.5 Billion Market Opportunity with ResMed, Koninklijke ...
www.businesswire.com - April 27 at 9:14 AM
ResMed (RMD) Q3 2018 Results - Earnings Call TranscriptResMed (RMD) Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - April 27 at 9:14 AM
ResMed (RMD) Posts Quarterly  Earnings Results, Beats Estimates By $0.08 EPSResMed (RMD) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - April 26 at 8:10 PM
ResMed Inc. (RMD) Plans Quarterly Dividend of $0.35ResMed Inc. (RMD) Plans Quarterly Dividend of $0.35
www.americanbankingnews.com - April 26 at 6:52 PM
Resmed Q3 18 Earnings Conference Call At 4:30 PM ETResmed Q3 18 Earnings Conference Call At 4:30 PM ET
www.nasdaq.com - April 26 at 4:55 PM
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2018ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2018
finance.yahoo.com - April 26 at 4:55 PM
ResMed: Fiscal 3Q Earnings SnapshotResMed: Fiscal 3Q Earnings Snapshot
finance.yahoo.com - April 26 at 4:55 PM
ResMed Inc. (RMD) Given Average Recommendation of "Hold" by BrokeragesResMed Inc. (RMD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 25 at 5:30 PM
ResMed Inc. (RMD) Expected to Post Quarterly Sales of $564.87 MillionResMed Inc. (RMD) Expected to Post Quarterly Sales of $564.87 Million
www.americanbankingnews.com - April 25 at 4:25 AM
ResMed (RMD) Stock Rating Lowered by UBSResMed (RMD) Stock Rating Lowered by UBS
www.americanbankingnews.com - April 24 at 9:29 AM
UBS & Macquarie deliver ratings on ResMed Inc. ahead of profit reportUBS & Macquarie deliver ratings on ResMed Inc. ahead of profit report
www.fool.com.au - April 24 at 8:48 AM
Analysis: Positioning to Benefit within Korn/Ferry International, ResMed, Donaldson, Ollies Bargain Outlet, VSE, and ...Analysis: Positioning to Benefit within Korn/Ferry International, ResMed, Donaldson, Ollie's Bargain Outlet, VSE, and ...
globenewswire.com - April 23 at 8:39 AM
Medical Equipment Stocks Research Reports Released on Myomo, Neovasc, ResMed, and Wright MedicalMedical Equipment Stocks' Research Reports Released on Myomo, Neovasc, ResMed, and Wright Medical
www.prnewswire.com - April 23 at 8:39 AM
Analysis: Positioning to Benefit within Korn/Ferry International, ResMed, Donaldson, Ollies Bargain Outlet, VSE, and STARWOOD PROPERTY TRUST, INC — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Korn/Ferry International, ResMed, Donaldson, Ollie's Bargain Outlet, VSE, and STARWOOD PROPERTY TRUST, INC — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - April 23 at 8:39 AM
Zacks: Brokerages Expect ResMed Inc. (RMD) to Announce $0.83 EPSZacks: Brokerages Expect ResMed Inc. (RMD) to Announce $0.83 EPS
www.americanbankingnews.com - April 23 at 7:16 AM
BRIEF-Resmed Says Co Entered Certain Amended And Restated Credit Agreement, Dated As Of Closing DateBRIEF-Resmed Says Co Entered Certain Amended And Restated Credit Agreement, Dated As Of Closing Date
www.reuters.com - April 20 at 8:58 AM
3 reasons why Im bullish on ResMed Inc. (CHESS)3 reasons why I'm bullish on ResMed Inc. (CHESS)
www.fool.com.au - April 20 at 8:58 AM
ResMed (RMD) Set to Announce Quarterly Earnings on ThursdayResMed (RMD) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 19 at 1:21 AM
Form 4 RESMED INC For: Apr 16 Filed by: Sandercock BrettForm 4 RESMED INC For: Apr 16 Filed by: Sandercock Brett
www.streetinsider.com - April 18 at 8:51 AM
William Blair Reiterates Outperform Rating for ResMed (RMD)William Blair Reiterates Outperform Rating for ResMed (RMD)
www.americanbankingnews.com - April 18 at 8:36 AM
ResMed Inc. (RMD) CFO Brett Sandercock Sells 2,000 SharesResMed Inc. (RMD) CFO Brett Sandercock Sells 2,000 Shares
www.americanbankingnews.com - April 17 at 10:33 PM
ResMed (RMD) Lowered to "Buy" at BidaskClubResMed (RMD) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 16 at 5:24 PM
Bank of America Lowers ResMed (RMD) to NeutralBank of America Lowers ResMed (RMD) to Neutral
www.americanbankingnews.com - April 14 at 11:49 AM
ResMed (RMD) Given "Sell" Rating at Needham & Company LLCResMed (RMD) Given "Sell" Rating at Needham & Company LLC
www.americanbankingnews.com - April 14 at 10:35 AM
ResMed (RMD) Downgraded to "Neutral" at Credit Suisse GroupResMed (RMD) Downgraded to "Neutral" at Credit Suisse Group
www.americanbankingnews.com - April 14 at 10:35 AM
ResMed (RMD) Upgraded by Citigroup to "Buy"ResMed (RMD) Upgraded by Citigroup to "Buy"
www.americanbankingnews.com - April 14 at 10:35 AM
ResMed (RMD) PT Raised to $70.00ResMed (RMD) PT Raised to $70.00
www.americanbankingnews.com - April 14 at 9:37 AM
ResMed (RMD) versus Baxter International (BAX) Financial AnalysisResMed (RMD) versus Baxter International (BAX) Financial Analysis
www.americanbankingnews.com - April 11 at 9:59 AM
Australia and New Zealand at healthcare cutting edgeAustralia and New Zealand at healthcare cutting edge
www.ft.com - April 10 at 5:02 PM
ResMed (RMD) Upgraded to Buy by Zacks Investment ResearchResMed (RMD) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 9 at 2:58 PM
ResMed Inc. (RMD) Expected to Post Quarterly Sales of $562.33 MillionResMed Inc. (RMD) Expected to Post Quarterly Sales of $562.33 Million
www.americanbankingnews.com - April 8 at 3:58 AM
ResMed Inc. (RMD) Expected to Post Earnings of $0.83 Per ShareResMed Inc. (RMD) Expected to Post Earnings of $0.83 Per Share
www.americanbankingnews.com - April 6 at 9:19 AM
JPMorgan Chase Boosts ResMed (RMD) Price Target to $73.00JPMorgan Chase Boosts ResMed (RMD) Price Target to $73.00
www.americanbankingnews.com - April 4 at 1:23 PM
ResMed (RMD) Rating Lowered to Neutral at CitigroupResMed (RMD) Rating Lowered to Neutral at Citigroup
www.americanbankingnews.com - April 4 at 12:49 PM

SEC Filings

ResMed (NYSE:RMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


ResMed (NYSE:RMD) Income Statement, Balance Sheet and Cash Flow Statement


ResMed (NYSE RMD) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.